MAP2K1 and cancer: Our results therefore suggest that screening cancer patient EVs for the presence of MEK1 could be a useful form of “personalized medicine” to select patient populations who most likely would respond to MEK inhibitors without the deleterious effects caused by inhibiting MEK1 activity in EVs.